|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
214 a.a.
|
|
|
|
|
|
|
|
|
|
|
237 a.a.
|
|
|
|
|
|
|
|
|
|
|
13 a.a.
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
|
PDB id:
|
|
|
|
| Name: |
|
Viral protein/immune system
|
|
|
Title:
|
|
Crystal structure of the broadly neutralizing anti-HIV-1 antibody 2f5 in complex with a gp41 11mer epitope
|
|
Structure:
|
|
Anti-HIV-1 antibody 2f5 light chain. Chain: l. Engineered: yes. Anti-HIV-1 antibody 2f5 heavy chain. Chain: h. Engineered: yes. Envelope glycoprotein gp41. Chain: p. Fragment: transmembrane glycoprotein (residues 659-669).
|
|
Source:
|
|
Homo sapiens. Human. Organism_taxid: 9606. Expressed in: cricetulus griseus. Expression_system_taxid: 10029. Expression_system_cell_line: cb-f7. Other_details: heteromyeloma cell line cb-f7 fused with peripheral blood mononuclear cells. Synthetic: yes.
|
|
Biol. unit:
|
|
Trimer (from
)
|
|
Resolution:
|
|
|
2.10Å
|
R-factor:
|
0.200
|
R-free:
|
0.233
|
|
|
Authors:
|
|
G.Ofek,M.Tang,A.Sambor,H.Katinger,J.R.Mascola,R.Wyatt,P.D.Kwong
|
|
Key ref:
|
|
G.Ofek
et al.
(2004).
Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.
J Virol,
78,
10724-10737.
PubMed id:
|
|
|
Date:
|
|
|
04-Jun-04
|
Release date:
|
05-Oct-04
|
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
|
Headers
|
|
|
|
References
|
|
|
|
|
|
|
|
No UniProt id for this chain
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
| |
|
|
J Virol
78:10724-10737
(2004)
|
|
PubMed id:
|
|
|
|
|
|
| |
|
Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.
|
|
G.Ofek,
M.Tang,
A.Sambor,
H.Katinger,
J.R.Mascola,
R.Wyatt,
P.D.Kwong.
|
|
|
|
|
| |
ABSTRACT
|
|
|
|
| |
|
|
The membrane-proximal region of the ectodomain of the gp41 envelope glycoprotein
of human immunodeficiency virus type 1 (HIV-1) is the target of three of the
five broadly neutralizing anti-HIV-1 antibodies thus far isolated. We have
determined crystal structures of the antigen-binding fragment for one of these
antibodies, 2F5, in complex with 7-mer, 11-mer, and 17-mer peptides of the gp41
membrane-proximal region, at 2.0-, 2.1-, and 2.2-A resolutions, respectively.
The structures reveal an extended gp41 conformation, which stretches over 30 A
in length. Contacts are made with five complementarity-determining regions of
the antibody as well as with nonpolymorphic regions. Only one exclusive charged
face of the gp41 epitope is bound by 2F5, while the nonbound face, which is
hydrophobic, may be hidden due to occlusion by other portions of the ectodomain.
The structures reveal that the 2F5 antibody is uniquely built to bind to an
epitope that is proximal to a membrane surface and in a manner mostly unaffected
by large-scale steric hindrance. Biochemical studies with proteoliposomes
confirm the importance of lipid membrane and hydrophobic context in the binding
of 2F5 as well as in the binding of 4E10, another broadly neutralizing antibody
that recognizes the membrane-proximal region of gp41. Based on these structural
and biochemical results, immunization strategies for eliciting 2F5- and
4E10-like broadly neutralizing anti-HIV-1 antibodies are proposed.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
|
| |
PubMed id
|
|
Reference
|
|
|
|
|
|
J.Huang,
G.Ofek,
L.Laub,
M.K.Louder,
N.A.Doria-Rose,
N.S.Longo,
H.Imamichi,
R.T.Bailer,
B.Chakrabarti,
S.K.Sharma,
S.M.Alam,
T.Wang,
Y.Yang,
B.Zhang,
S.A.Migueles,
R.Wyatt,
B.F.Haynes,
P.D.Kwong,
J.R.Mascola,
and
M.Connors
(2012).
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody.
|
| |
Nature,
491,
406-412.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
C.R.Gregor,
E.Cerasoli,
P.R.Tulip,
M.G.Ryadnov,
G.J.Martyna,
and
J.Crain
(2011).
Autonomous folding in the membrane proximal HIV peptide gp41(659-671): pH tuneability at micelle interfaces.
|
| |
Phys Chem Chem Phys,
13,
127-135.
|
|
|
|
|
|
|
D.K.Wijesundara,
R.J.Jackson,
I.A.Ramshaw,
and
C.Ranasinghe
(2011).
Human immunodeficiency virus-1 vaccine design: where do we go now?
|
| |
Immunol Cell Biol,
89,
367-374.
|
|
|
|
|
|
|
D.Lamb,
A.W.Schüttelkopf,
D.M.van Aalten,
and
D.W.Brighty
(2011).
Charge-surrounded pockets and electrostatic interactions with small ions modulate the activity of retroviral fusion proteins.
|
| |
PLoS Pathog,
7,
e1001268.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
F.Breden,
C.Lepik,
N.S.Longo,
M.Montero,
P.E.Lipsky,
and
J.K.Scott
(2011).
Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease.
|
| |
PLoS One,
6,
e16857.
|
|
|
|
|
|
|
J.Guenaga,
P.Dosenovic,
G.Ofek,
D.Baker,
W.R.Schief,
P.D.Kwong,
G.B.Karlsson Hedestam,
and
R.T.Wyatt
(2011).
Heterologous Epitope-Scaffold Prime∶Boosting Immuno-Focuses B Cell Responses to the HIV-1 gp41 2F5 Neutralization Determinant.
|
| |
PLoS One,
6,
e16074.
|
|
|
|
|
|
|
J.Wang,
P.Tong,
L.Lu,
L.Zhou,
L.Xu,
S.Jiang,
and
Y.H.Chen
(2011).
HIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodies.
|
| |
PLoS One,
6,
e18233.
|
|
|
|
|
|
|
M.Kim,
Z.Y.Sun,
K.D.Rand,
X.Shi,
L.Song,
Y.Cheng,
A.F.Fahmy,
S.Majumdar,
G.Ofek,
Y.Yang,
P.D.Kwong,
J.H.Wang,
J.R.Engen,
G.Wagner,
and
E.L.Reinherz
(2011).
Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization.
|
| |
Nat Struct Mol Biol,
18,
1235-1243.
|
|
|
|
|
|
|
X.Shen,
and
G.D.Tomaras
(2011).
Alterations of the B-cell response by HIV-1 replication.
|
| |
Curr HIV/AIDS Rep,
8,
23-30.
|
|
|
|
|
|
|
A.A.Waheed,
S.D.Ablan,
R.C.Sowder,
J.D.Roser,
C.P.Schaffner,
E.Chertova,
and
E.O.Freed
(2010).
Effect of mutations in the human immunodeficiency virus type 1 protease on cleavage of the gp41 cytoplasmic tail.
|
| |
J Virol,
84,
3121-3126.
|
|
|
|
|
|
|
A.J.McMichael,
P.Borrow,
G.D.Tomaras,
N.Goonetilleke,
and
B.F.Haynes
(2010).
The immune response during acute HIV-1 infection: clues for vaccine development.
|
| |
Nat Rev Immunol,
10,
11-23.
|
|
|
|
|
|
|
A.Mader,
and
R.Kunert
(2010).
Humanization strategies for an anti-idiotypic antibody mimicking HIV-1 gp41.
|
| |
Protein Eng Des Sel,
23,
947-954.
|
|
|
|
|
|
|
B.E.Correia,
Y.E.Ban,
M.A.Holmes,
H.Xu,
K.Ellingson,
Z.Kraft,
C.Carrico,
E.Boni,
D.N.Sather,
C.Zenobia,
K.Y.Burke,
T.Bradley-Hewitt,
J.F.Bruhn-Johannsen,
O.Kalyuzhniy,
D.Baker,
R.K.Strong,
L.Stamatatos,
and
W.R.Schief
(2010).
Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope.
|
| |
Structure,
18,
1116-1126.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
B.F.Haynes,
N.I.Nicely,
and
S.M.Alam
(2010).
HIV-1 autoreactive antibodies: are they good or bad for HIV-1 prevention?
|
| |
Nat Struct Mol Biol,
17,
543-545.
|
|
|
|
|
|
|
D.P.Leaman,
H.Kinkead,
and
M.B.Zwick
(2010).
In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1.
|
| |
J Virol,
84,
3382-3395.
|
|
|
|
|
|
|
D.R.Burton
(2010).
Scaffolding to build a rational vaccine design strategy.
|
| |
Proc Natl Acad Sci U S A,
107,
17859-17860.
|
|
|
|
|
|
|
E.M.Scherer,
D.P.Leaman,
M.B.Zwick,
A.J.McMichael,
and
D.R.Burton
(2010).
Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions.
|
| |
Proc Natl Acad Sci U S A,
107,
1529-1534.
|
|
|
|
|
|
|
G.Frey,
J.Chen,
S.Rits-Volloch,
M.M.Freeman,
S.Zolla-Pazner,
and
B.Chen
(2010).
Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies.
|
| |
Nat Struct Mol Biol,
17,
1486-1491.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
G.Ofek,
F.J.Guenaga,
W.R.Schief,
J.Skinner,
D.Baker,
R.Wyatt,
and
P.D.Kwong
(2010).
Elicitation of structure-specific antibodies by epitope scaffolds.
|
| |
Proc Natl Acad Sci U S A,
107,
17880-17887.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
G.Ofek,
K.McKee,
Y.Yang,
Z.Y.Yang,
J.Skinner,
F.J.Guenaga,
R.Wyatt,
M.B.Zwick,
G.J.Nabel,
J.R.Mascola,
and
P.D.Kwong
(2010).
Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region.
|
| |
J Virol,
84,
2955-2962.
|
|
|
|
|
|
|
H.Xu,
L.Song,
M.Kim,
M.A.Holmes,
Z.Kraft,
G.Sellhorn,
E.L.Reinherz,
L.Stamatatos,
and
R.K.Strong
(2010).
Interactions between lipids and human anti-HIV antibody 4E10 can be reduced without ablating neutralizing activity.
|
| |
J Virol,
84,
1076-1088.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
J.A.Hoxie
(2010).
Toward an antibody-based HIV-1 vaccine.
|
| |
Annu Rev Med,
61,
135-152.
|
|
|
|
|
|
|
J.Liu,
Y.Deng,
Q.Li,
A.K.Dey,
J.P.Moore,
and
M.Lu
(2010).
Role of a putative gp41 dimerization domain in human immunodeficiency virus type 1 membrane fusion.
|
| |
J Virol,
84,
201-209.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
J.Nie,
A.Song,
S.Xu,
X.Li,
and
Y.Wang
(2010).
The effect of human immunodeficiency virus type 1 (HIV-1) gp41 variability on antibody detection.
|
| |
Arch Virol,
155,
1813-1822.
|
|
|
|
|
|
|
J.P.Julien,
N.Huarte,
R.Maeso,
S.G.Taneva,
A.Cunningham,
J.L.Nieva,
and
E.F.Pai
(2010).
Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding.
|
| |
J Virol,
84,
4136-4147.
|
|
|
|
|
|
|
J.R.Mascola,
and
D.C.Montefiori
(2010).
The role of antibodies in HIV vaccines.
|
| |
Annu Rev Immunol,
28,
413-444.
|
|
|
|
|
|
|
J.S.Klein,
and
P.J.Bjorkman
(2010).
Few and far between: how HIV may be evading antibody avidity.
|
| |
PLoS Pathog,
6,
e1000908.
|
|
|
|
|
|
|
K.J.Doores,
Z.Fulton,
V.Hong,
M.K.Patel,
C.N.Scanlan,
M.R.Wormald,
M.G.Finn,
D.R.Burton,
I.A.Wilson,
and
B.G.Davis
(2010).
A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity.
|
| |
Proc Natl Acad Sci U S A,
107,
17107-17112.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
L.J.Gamble,
and
Q.L.Matthews
(2010).
Current progress in the development of a prophylactic vaccine for HIV-1.
|
| |
Drug Des Devel Ther,
5,
9.
|
|
|
|
|
|
|
L.M.Walker,
and
D.R.Burton
(2010).
Rational antibody-based HIV-1 vaccine design: current approaches and future directions.
|
| |
Curr Opin Immunol,
22,
358-366.
|
|
|
|
|
|
|
M.Lapelosa,
G.F.Arnold,
E.Gallicchio,
E.Arnold,
and
R.M.Levy
(2010).
Antigenic characteristics of rhinovirus chimeras designed in silico for enhanced presentation of HIV-1 gp41 epitopes [corrected].
|
| |
J Mol Biol,
397,
752-766.
|
|
|
|
|
|
|
M.Pancera,
J.S.McLellan,
X.Wu,
J.Zhu,
A.Changela,
S.D.Schmidt,
Y.Yang,
T.Zhou,
S.Phogat,
J.R.Mascola,
and
P.D.Kwong
(2010).
Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1.
|
| |
J Virol,
84,
8098-8110.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
N.I.Nicely,
S.M.Dennison,
L.Spicer,
R.M.Scearce,
G.Kelsoe,
Y.Ueda,
H.Chen,
H.X.Liao,
S.M.Alam,
and
B.F.Haynes
(2010).
Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external region.
|
| |
Nat Struct Mol Biol,
17,
1492-1494.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
P.Wang,
and
X.Yang
(2010).
Neutralization efficiency is greatly enhanced by bivalent binding of an antibody to epitopes in the V4 region and the membrane-proximal external region within one trimer of human immunodeficiency virus type 1 glycoproteins.
|
| |
J Virol,
84,
7114-7123.
|
|
|
|
|
|
|
Q.L.Matthews,
A.Fatima,
Y.Tang,
B.A.Perry,
Y.Tsuruta,
S.Komarova,
L.Timares,
C.Zhao,
N.Makarova,
A.V.Borovjagin,
P.L.Stewart,
H.Wu,
J.L.Blackwell,
and
D.T.Curiel
(2010).
HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach.
|
| |
PLoS One,
5,
e11815.
|
|
|
|
|
|
|
R.Diskin,
P.M.Marcovecchio,
and
P.J.Bjorkman
(2010).
Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity.
|
| |
Nat Struct Mol Biol,
17,
608-613.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
R.Pejchal,
L.M.Walker,
R.L.Stanfield,
S.K.Phogat,
W.C.Koff,
P.Poignard,
D.R.Burton,
and
I.A.Wilson
(2010).
Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1.
|
| |
Proc Natl Acad Sci U S A,
107,
11483-11488.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
S.Gnanakaran,
M.G.Daniels,
T.Bhattacharya,
A.S.Lapedes,
A.Sethi,
M.Li,
H.Tang,
K.Greene,
H.Gao,
B.F.Haynes,
M.S.Cohen,
G.M.Shaw,
M.S.Seaman,
A.Kumar,
F.Gao,
D.C.Montefiori,
and
B.Korber
(2010).
Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies.
|
| |
PLoS Comput Biol,
6,
e1000955.
|
|
|
|
|
|
|
S.Hearty,
P.J.Conroy,
B.V.Ayyar,
B.Byrne,
and
R.O'Kennedy
(2010).
Surface plasmon resonance for vaccine design and efficacy studies: recent applications and future trends.
|
| |
Expert Rev Vaccines,
9,
645-664.
|
|
|
|
|
|
|
S.Ingale,
J.S.Gach,
M.B.Zwick,
and
P.E.Dawson
(2010).
Synthesis and analysis of the membrane proximal external region epitopes of HIV-1.
|
| |
J Pept Sci,
16,
716-722.
|
|
|
|
|
|
|
T.Zhou,
I.Georgiev,
X.Wu,
Z.Y.Yang,
K.Dai,
A.Finzi,
Y.D.Kwon,
J.F.Scheid,
W.Shi,
L.Xu,
Y.Yang,
J.Zhu,
M.C.Nussenzweig,
J.Sodroski,
L.Shapiro,
G.J.Nabel,
J.R.Mascola,
and
P.D.Kwong
(2010).
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01.
|
| |
Science,
329,
811-817.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
V.Buzon,
G.Natrajan,
D.Schibli,
F.Campelo,
M.M.Kozlov,
and
W.Weissenhorn
(2010).
Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions.
|
| |
PLoS Pathog,
6,
e1000880.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
W.W.Koh,
A.Forsman,
S.Hué,
G.J.van der Velden,
D.L.Yirrell,
A.McKnight,
R.A.Weiss,
and
M.M.Aasa-Chapman
(2010).
Novel subtype C human immunodeficiency virus type 1 envelopes cloned directly from plasma: coreceptor usage and neutralization phenotypes.
|
| |
J Gen Virol,
91,
2374-2380.
|
|
|
|
|
|
|
X.Shen,
S.M.Dennison,
P.Liu,
F.Gao,
F.Jaeger,
D.C.Montefiori,
L.Verkoczy,
B.F.Haynes,
S.M.Alam,
and
G.D.Tomaras
(2010).
Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution.
|
| |
Proc Natl Acad Sci U S A,
107,
5972-5977.
|
|
|
|
|
|
|
A.Mor,
E.Segal,
B.Mester,
B.Arshava,
O.Rosen,
F.X.Ding,
J.Russo,
A.Dafni,
F.Schvartzman,
T.Scherf,
F.Naider,
and
J.Anglister
(2009).
Mimicking the structure of the V3 epitope bound to HIV-1 neutralizing antibodies.
|
| |
Biochemistry,
48,
3288-3303.
|
|
|
|
|
|
|
A.S.Veiga,
L.K.Pattenden,
J.M.Fletcher,
M.A.Castanho,
and
M.I.Aguilar
(2009).
Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems.
|
| |
Chembiochem,
10,
1032-1044.
|
|
|
|
|
|
|
D.S.Watson,
and
F.C.Szoka
(2009).
Role of lipid structure in the humoral immune response in mice to covalent lipid-peptides from the membrane proximal region of HIV-1 gp41.
|
| |
Vaccine,
27,
4672-4683.
|
|
|
|
|
|
|
D.S.Watson,
Z.Huang,
and
F.C.Szoka
(2009).
All-trans retinoic acid potentiates the antibody response in mice to a lipopeptide antigen adjuvanted with liposomal lipid A.
|
| |
Immunol Cell Biol,
87,
630-633.
|
|
|
|
|
|
|
D.Tudor,
M.Derrien,
L.Diomede,
A.S.Drillet,
M.Houimel,
C.Moog,
J.M.Reynes,
L.Lopalco,
and
M.Bomsel
(2009).
HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis.
|
| |
Mucosal Immunol,
2,
412-426.
|
|
|
|
|
|
|
E.S.Gray,
M.C.Madiga,
P.L.Moore,
K.Mlisana,
S.S.Abdool Karim,
J.M.Binley,
G.M.Shaw,
J.R.Mascola,
and
L.Morris
(2009).
Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region.
|
| |
J Virol,
83,
11265-11274.
|
|
|
|
|
|
|
F.G.Hermann,
H.Martinius,
M.Egelhofer,
T.Giroglou,
T.Tonn,
S.D.Roth,
R.Zahn,
P.Schult-Dietrich,
A.Alexandrov,
U.Dietrich,
C.Baum,
and
D.von Laer
(2009).
Protein scaffold and expression level determine antiviral activity of membrane-anchored antiviral peptides.
|
| |
Hum Gene Ther,
20,
325-336.
|
|
|
|
|
|
|
F.Naider,
and
J.Anglister
(2009).
Peptides in the treatment of AIDS.
|
| |
Curr Opin Struct Biol,
19,
473-482.
|
|
|
|
|
|
|
G.F.Arnold,
P.K.Velasco,
A.K.Holmes,
T.Wrin,
S.C.Geisler,
P.Phung,
Y.Tian,
D.A.Resnick,
X.Ma,
T.M.Mariano,
C.J.Petropoulos,
J.W.Taylor,
H.Katinger,
and
E.Arnold
(2009).
Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope.
|
| |
J Virol,
83,
5087-5100.
|
|
|
|
|
|
|
G.R.Matyas,
L.Wieczorek,
Z.Beck,
C.Ochsenbauer-Jambor,
J.C.Kappes,
N.L.Michael,
V.R.Polonis,
and
C.R.Alving
(2009).
Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes.
|
| |
AIDS,
23,
2069-2077.
|
|
|
|
|
|
|
H.X.Liao,
M.C.Levesque,
A.Nagel,
A.Dixon,
R.Zhang,
E.Walter,
R.Parks,
J.Whitesides,
D.J.Marshall,
K.K.Hwang,
Y.Yang,
X.Chen,
F.Gao,
S.Munshaw,
T.B.Kepler,
T.Denny,
M.A.Moody,
and
B.F.Haynes
(2009).
High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies.
|
| |
J Virol Methods,
158,
171-179.
|
|
|
|
|
|
|
J.Liu,
Y.Deng,
A.K.Dey,
J.P.Moore,
and
M.Lu
(2009).
Structure of the HIV-1 gp41 membrane-proximal ectodomain region in a putative prefusion conformation.
|
| |
Biochemistry,
48,
2915-2923.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
K.L.Davis,
F.Bibollet-Ruche,
H.Li,
J.M.Decker,
O.Kutsch,
L.Morris,
A.Salomon,
A.Pinter,
J.A.Hoxie,
B.H.Hahn,
P.D.Kwong,
and
G.M.Shaw
(2009).
Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma.
|
| |
J Virol,
83,
1240-1259.
|
|
|
|
|
|
|
L.G.Perez,
M.R.Costa,
C.A.Todd,
B.F.Haynes,
and
D.C.Montefiori
(2009).
Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41.
|
| |
J Virol,
83,
7397-7410.
|
|
|
|
|
|
|
L.Song,
Z.Y.Sun,
K.E.Coleman,
M.B.Zwick,
J.S.Gach,
J.H.Wang,
E.L.Reinherz,
G.Wagner,
and
M.Kim
(2009).
Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface.
|
| |
Proc Natl Acad Sci U S A,
106,
9057-9062.
|
|
|
|
|
|
|
L.Verkoczy,
M.A.Moody,
T.M.Holl,
H.Bouton-Verville,
R.M.Scearce,
J.Hutchinson,
S.M.Alam,
G.Kelsoe,
and
B.F.Haynes
(2009).
Functional, non-clonal IgMa-restricted B cell receptor interactions with the HIV-1 envelope gp41 membrane proximal external region.
|
| |
PLoS One,
4,
e7215.
|
|
|
|
|
|
|
M.Lapelosa,
E.Gallicchio,
G.F.Arnold,
E.Arnold,
and
R.M.Levy
(2009).
In silico vaccine design based on molecular simulations of rhinovirus chimeras presenting HIV-1 gp41 epitopes.
|
| |
J Mol Biol,
385,
675-691.
|
|
|
|
|
|
|
P.D.Kwong,
and
I.A.Wilson
(2009).
HIV-1 and influenza antibodies: seeing antigens in new ways.
|
| |
Nat Immunol,
10,
573-578.
|
|
|
|
|
|
|
P.M.Colman
(2009).
New antivirals and drug resistance.
|
| |
Annu Rev Biochem,
78,
95.
|
|
|
|
|
|
|
R.Pejchal,
J.S.Gach,
F.M.Brunel,
R.M.Cardoso,
R.L.Stanfield,
P.E.Dawson,
D.R.Burton,
M.B.Zwick,
and
I.A.Wilson
(2009).
A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies.
|
| |
J Virol,
83,
8451-8462.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
S.Bryson,
J.P.Julien,
R.C.Hynes,
and
E.F.Pai
(2009).
Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications.
|
| |
J Virol,
83,
11862-11875.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
S.M.Alam,
M.Morelli,
S.M.Dennison,
H.X.Liao,
R.Zhang,
S.M.Xia,
S.Rits-Volloch,
L.Sun,
S.C.Harrison,
B.F.Haynes,
and
B.Chen
(2009).
Role of HIV membrane in neutralization by two broadly neutralizing antibodies.
|
| |
Proc Natl Acad Sci U S A,
106,
20234-20239.
|
|
|
|
|
|
|
S.M.Dennison,
S.M.Stewart,
K.C.Stempel,
H.X.Liao,
B.F.Haynes,
and
S.M.Alam
(2009).
Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions.
|
| |
J Virol,
83,
10211-10223.
|
|
|
|
|
|
|
S.S.Chen,
P.Yang,
P.Y.Ke,
H.F.Li,
W.E.Chan,
D.K.Chang,
C.K.Chuang,
Y.Tsai,
and
S.C.Huang
(2009).
Identification of the LWYIK motif located in the human immunodeficiency virus type 1 transmembrane gp41 protein as a distinct determinant for viral infection.
|
| |
J Virol,
83,
870-883.
|
|
|
|
|
|
|
S.X.Du,
R.J.Idiart,
E.B.Mariano,
H.Chen,
P.Jiang,
L.Xu,
K.M.Ostrow,
T.Wrin,
P.Phung,
J.M.Binley,
C.J.Petropoulos,
J.A.Ballantyne,
and
R.G.Whalen
(2009).
Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein.
|
| |
Virology,
395,
33-44.
|
|
|
|
|
|
|
T.Ura,
A.Yoshida,
K.Q.Xin,
S.Yoshizaki,
S.Yashima,
S.Abe,
H.Mizuguchi,
and
K.Okuda
(2009).
Designed recombinant adenovirus type 5 vector induced envelope-specific CD8(+) cytotoxic T lymphocytes and cross-reactive neutralizing antibodies against human immunodeficiency virus type 1.
|
| |
J Gene Med,
11,
139-149.
|
|
|
|
|
|
|
W.Yuan,
X.Li,
M.Kasterka,
M.K.Gorny,
S.Zolla-Pazner,
and
J.Sodroski
(2009).
Oligomer-specific conformations of the human immunodeficiency virus (HIV-1) gp41 envelope glycoprotein ectodomain recognized by human monoclonal antibodies.
|
| |
AIDS Res Hum Retroviruses,
25,
319-328.
|
|
|
|
|
|
|
X.Shen,
R.J.Parks,
D.C.Montefiori,
J.L.Kirchherr,
B.F.Keele,
J.M.Decker,
W.A.Blattner,
F.Gao,
K.J.Weinhold,
C.B.Hicks,
M.L.Greenberg,
B.H.Hahn,
G.M.Shaw,
B.F.Haynes,
and
G.D.Tomaras
(2009).
In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.
|
| |
J Virol,
83,
3617-3625.
|
|
|
|
|
|
|
A.Penn-Nicholson,
D.P.Han,
S.J.Kim,
H.Park,
R.Ansari,
D.C.Montefiori,
and
M.W.Cho
(2008).
Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope.
|
| |
Virology,
372,
442-456.
|
|
|
|
|
|
|
B.F.Haynes,
and
S.M.Alam
(2008).
HIV-1 hides an Achilles' heel in virion lipids.
|
| |
Immunity,
28,
10-12.
|
|
|
|
|
|
|
C.H.Bell,
R.Pantophlet,
A.Schiefner,
L.A.Cavacini,
R.L.Stanfield,
D.R.Burton,
and
I.A.Wilson
(2008).
Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization.
|
| |
J Mol Biol,
375,
969-978.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
E.Noah,
Z.Biron,
F.Naider,
B.Arshava,
and
J.Anglister
(2008).
The membrane proximal external region of the HIV-1 envelope glycoprotein gp41 contributes to the stabilization of the six-helix bundle formed with a matching N' peptide.
|
| |
Biochemistry,
47,
6782-6792.
|
|
|
|
|
|
|
E.S.Gray,
P.L.Moore,
F.Bibollet-Ruche,
H.Li,
J.M.Decker,
T.Meyers,
G.M.Shaw,
and
L.Morris
(2008).
4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response.
|
| |
J Virol,
82,
2367-2375.
|
|
|
|
|
|
|
E.T.Crooks,
P.Jiang,
M.Franti,
S.Wong,
M.B.Zwick,
J.A.Hoxie,
J.E.Robinson,
P.L.Moore,
and
J.M.Binley
(2008).
Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization.
|
| |
Virology,
377,
364-378.
|
|
|
|
|
|
|
G.B.Karlsson Hedestam,
R.A.Fouchier,
S.Phogat,
D.R.Burton,
J.Sodroski,
and
R.T.Wyatt
(2008).
The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.
|
| |
Nat Rev Microbiol,
6,
143-155.
|
|
|
|
|
|
|
G.Frey,
H.Peng,
S.Rits-Volloch,
M.Morelli,
Y.Cheng,
and
B.Chen
(2008).
A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies.
|
| |
Proc Natl Acad Sci U S A,
105,
3739-3744.
|
|
|
|
|
|
|
J.G.Joyce,
I.J.Krauss,
H.C.Song,
D.W.Opalka,
K.M.Grimm,
D.D.Nahas,
M.T.Esser,
R.Hrin,
M.Feng,
V.Y.Dudkin,
M.Chastain,
J.W.Shiver,
and
S.J.Danishefsky
(2008).
An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions.
|
| |
Proc Natl Acad Sci U S A,
105,
15684-15689.
|
|
|
|
|
|
|
J.M.White,
S.E.Delos,
M.Brecher,
and
K.Schornberg
(2008).
Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme.
|
| |
Crit Rev Biochem Mol Biol,
43,
189-219.
|
|
|
|
|
|
|
M.A.Moody,
and
B.F.Haynes
(2008).
Antigen-specific B cell detection reagents: use and quality control.
|
| |
Cytometry A,
73,
1086-1092.
|
|
|
|
|
|
|
M.Montero,
N.E.van Houten,
X.Wang,
and
J.K.Scott
(2008).
The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.
|
| |
Microbiol Mol Biol Rev,
72,
54.
|
|
|
|
|
|
|
M.Y.Zhang,
B.K.Vu,
A.Choudhary,
H.Lu,
M.Humbert,
H.Ong,
M.Alam,
R.M.Ruprecht,
G.Quinnan,
S.Jiang,
D.C.Montefiori,
J.R.Mascola,
C.C.Broder,
B.F.Haynes,
and
D.S.Dimitrov
(2008).
Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens.
|
| |
J Virol,
82,
6869-6879.
|
|
|
|
|
|
|
N.Huarte,
M.Lorizate,
R.Maeso,
R.Kunert,
R.Arranz,
J.M.Valpuesta,
and
J.L.Nieva
(2008).
The broadly neutralizing anti-human immunodeficiency virus type 1 4E10 monoclonal antibody is better adapted to membrane-bound epitope recognition and blocking than 2F5.
|
| |
J Virol,
82,
8986-8996.
|
|
|
|
|
|
|
P.Zhu,
H.Winkler,
E.Chertova,
K.A.Taylor,
and
K.H.Roux
(2008).
Cryoelectron tomography of HIV-1 envelope spikes: further evidence for tripod-like legs.
|
| |
PLoS Pathog,
4,
e1000203.
|
|
|
|
|
|
|
R.L.Schelonka,
M.Zemlin,
R.Kobayashi,
G.C.Ippolito,
Y.Zhuang,
G.L.Gartland,
A.Szalai,
K.Fujihashi,
K.Rajewsky,
and
H.W.Schroeder
(2008).
Preferential use of DH reading frame 2 alters B cell development and antigen-specific antibody production.
|
| |
J Immunol,
181,
8409-8415.
|
|
|
|
|
|
|
S.A.Vishwanathan,
and
E.Hunter
(2008).
Importance of the membrane-perturbing properties of the membrane-proximal external region of human immunodeficiency virus type 1 gp41 to viral fusion.
|
| |
J Virol,
82,
5118-5126.
|
|
|
|
|
|
|
S.M.Alam,
R.M.Scearce,
R.J.Parks,
K.Plonk,
S.G.Plonk,
L.L.Sutherland,
M.K.Gorny,
S.Zolla-Pazner,
S.Vanleeuwen,
M.A.Moody,
S.M.Xia,
D.C.Montefiori,
G.D.Tomaras,
K.J.Weinhold,
S.A.Karim,
C.B.Hicks,
H.X.Liao,
J.Robinson,
G.M.Shaw,
and
B.F.Haynes
(2008).
Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection.
|
| |
J Virol,
82,
115-125.
|
|
|
|
|
|
|
S.Phogat,
K.Svehla,
M.Tang,
A.Spadaccini,
J.Muller,
J.Mascola,
I.Berkower,
and
R.Wyatt
(2008).
Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles.
|
| |
Virology,
373,
72-84.
|
|
|
|
|
|
|
Z.Y.Sun,
K.J.Oh,
M.Kim,
J.Yu,
V.Brusic,
L.Song,
Z.Qiao,
J.H.Wang,
G.Wagner,
and
E.L.Reinherz
(2008).
HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane.
|
| |
Immunity,
28,
52-63.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
A.Manrique,
P.Rusert,
B.Joos,
M.Fischer,
H.Kuster,
C.Leemann,
B.Niederöst,
R.Weber,
G.Stiegler,
H.Katinger,
H.F.Günthard,
and
A.Trkola
(2007).
In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.
|
| |
J Virol,
81,
8793-8808.
|
|
|
|
|
|
|
B.Dey,
M.Pancera,
K.Svehla,
Y.Shu,
S.H.Xiang,
J.Vainshtein,
Y.Li,
J.Sodroski,
P.D.Kwong,
J.R.Mascola,
and
R.Wyatt
(2007).
Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity.
|
| |
J Virol,
81,
5579-5593.
|
|
|
|
|
|
|
C.A.Blish,
R.Nedellec,
K.Mandaliya,
D.E.Mosier,
and
J.Overbaugh
(2007).
HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.
|
| |
AIDS,
21,
693-702.
|
|
|
|
|
|
|
C.N.Scanlan,
J.Offer,
N.Zitzmann,
and
R.A.Dwek
(2007).
Exploiting the defensive sugars of HIV-1 for drug and vaccine design.
|
| |
Nature,
446,
1038-1045.
|
|
|
|
|
|
|
E.M.Scherer,
M.B.Zwick,
L.Teyton,
and
D.R.Burton
(2007).
Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity.
|
| |
AIDS,
21,
2131-2139.
|
|
|
|
|
|
|
J.D.Nelson,
F.M.Brunel,
R.Jensen,
E.T.Crooks,
R.M.Cardoso,
M.Wang,
A.Hessell,
I.A.Wilson,
J.M.Binley,
P.E.Dawson,
D.R.Burton,
and
M.B.Zwick
(2007).
An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.
|
| |
J Virol,
81,
4033-4043.
|
|
|
|
|
|
|
K.H.Roux,
and
K.A.Taylor
(2007).
AIDS virus envelope spike structure.
|
| |
Curr Opin Struct Biol,
17,
244-252.
|
|
|
|
|
|
|
M.H.Van Regenmortel
(2007).
The rational design of biological complexity: a deceptive metaphor.
|
| |
Proteomics,
7,
965-975.
|
|
|
|
|
|
|
M.Huber,
and
A.Trkola
(2007).
Humoral immunity to HIV-1: neutralization and beyond.
|
| |
J Intern Med,
262,
5.
|
|
|
|
|
|
|
M.Kim,
Z.Qiao,
J.Yu,
D.Montefiori,
and
E.L.Reinherz
(2007).
Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state.
|
| |
Vaccine,
25,
5102-5114.
|
|
|
|
|
|
|
M.Law,
R.M.Cardoso,
I.A.Wilson,
and
D.R.Burton
(2007).
Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy.
|
| |
J Virol,
81,
4272-4285.
|
|
|
|
|
|
|
N.C.Sheppard,
S.L.Davies,
S.A.Jeffs,
S.M.Vieira,
and
Q.J.Sattentau
(2007).
Production and characterization of high-affinity human monoclonal antibodies to human immunodeficiency virus type 1 envelope glycoproteins in a mouse model expressing human immunoglobulins.
|
| |
Clin Vaccine Immunol,
14,
157-167.
|
|
|
|
|
|
|
P.W.Mobley,
J.A.Barry,
A.J.Waring,
M.A.Sherman,
and
L.M.Gordon
(2007).
Membrane perturbing actions of HIV type 1 glycoprotein 41 domains are inhibited by helical C-peptides.
|
| |
AIDS Res Hum Retroviruses,
23,
224-242.
|
|
|
|
|
|
|
S.Giannecchini,
A.M.D'Ursi,
C.Esposito,
M.Scrima,
E.Zabogli,
G.Freer,
P.Rovero,
and
M.Bendinelli
(2007).
Antibodies generated in cats by a lipopeptide reproducing the membrane-proximal external region of the feline immunodeficiency virus transmembrane enhance virus infectivity.
|
| |
Clin Vaccine Immunol,
14,
944-951.
|
|
|
|
|
|
|
S.K.Phogat,
S.M.Kaminsky,
and
W.C.Koff
(2007).
HIV-1 rational vaccine design: molecular details of b12-gp120 complex structure.
|
| |
Expert Rev Vaccines,
6,
319-321.
|
|
|
|
|
|
|
S.M.Alam,
M.McAdams,
D.Boren,
M.Rak,
R.M.Scearce,
F.Gao,
Z.T.Camacho,
D.Gewirth,
G.Kelsoe,
P.Chen,
and
B.F.Haynes
(2007).
The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes.
|
| |
J Immunol,
178,
4424-4435.
|
|
|
|
|
|
|
S.Phogat,
R.T.Wyatt,
and
G.B.Karlsson Hedestam
(2007).
Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets.
|
| |
J Intern Med,
262,
26-43.
|
|
|
|
|
|
|
A.J.McMichael
(2006).
HIV vaccines.
|
| |
Annu Rev Immunol,
24,
227-255.
|
|
|
|
|
|
|
B.F.Haynes,
and
D.C.Montefiori
(2006).
Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.
|
| |
Expert Rev Vaccines,
5,
347-363.
|
|
|
|
|
|
|
B.F.Haynes,
and
D.C.Montefiori
(2006).
Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.
|
| |
Expert Rev Vaccines,
5,
579-595.
|
|
|
|
|
|
|
E.E.Verity,
L.A.Williams,
D.N.Haddad,
V.Choy,
C.O'Loughlin,
C.Chatfield,
N.K.Saksena,
A.Cunningham,
F.Gelder,
and
D.A.McPhee
(2006).
Broad neutralization and complement-mediated lysis of HIV-1 by PEHRG214, a novel caprine anti-HIV-1 polyclonal antibody.
|
| |
AIDS,
20,
505-515.
|
|
|
|
|
|
|
E.S.Gray,
T.Meyers,
G.Gray,
D.C.Montefiori,
and
L.Morris
(2006).
Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B.
|
| |
PLoS Med,
3,
e255.
|
|
|
|
|
|
|
E.Yuste,
H.B.Sanford,
J.Carmody,
J.Bixby,
S.Little,
M.B.Zwick,
T.Greenough,
D.R.Burton,
D.D.Richman,
R.C.Desrosiers,
and
W.E.Johnson
(2006).
Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.
|
| |
J Virol,
80,
3030-3041.
|
|
|
|
|
|
|
F.M.Brunel,
M.B.Zwick,
R.M.Cardoso,
J.D.Nelson,
I.A.Wilson,
D.R.Burton,
and
P.E.Dawson
(2006).
Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody.
|
| |
J Virol,
80,
1680-1687.
|
|
|
|
|
|
|
M.A.Rey-Cuillé,
J.Svab,
R.Benferhat,
B.Krust,
J.P.Briand,
S.Muller,
and
A.G.Hovanessian
(2006).
HIV-1 neutralizing antibodies elicited by the candidate CBD1 epitope vaccine react with the conserved caveolin-1 binding motif of viral glycoprotein gp41.
|
| |
J Pharm Pharmacol,
58,
759-767.
|
|
|
|
|
|
|
M.Braibant,
S.Brunet,
D.Costagliola,
C.Rouzioux,
H.Agut,
H.Katinger,
B.Autran,
and
F.Barin
(2006).
Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.
|
| |
AIDS,
20,
1923-1930.
|
|
|
|
|
|
|
N.E.van Houten,
M.B.Zwick,
A.Menendez,
and
J.K.Scott
(2006).
Filamentous phage as an immunogenic carrier to elicit focused antibody responses against a synthetic peptide.
|
| |
Vaccine,
24,
4188-4200.
|
|
|
|
|
|
|
P.Zhu,
J.Liu,
J.Bess,
E.Chertova,
J.D.Lifson,
H.Grisé,
G.A.Ofek,
K.A.Taylor,
and
K.H.Roux
(2006).
Distribution and three-dimensional structure of AIDS virus envelope spikes.
|
| |
Nature,
441,
847-852.
|
|
|
|
|
|
|
S.Beddows,
M.Kirschner,
L.Campbell-Gardener,
M.Franti,
A.K.Dey,
S.P.Iyer,
P.J.Maddon,
M.Paluch,
A.Master,
J.Overbaugh,
T.VanCott,
W.C.Olson,
and
J.P.Moore
(2006).
Construction and characterization of soluble, cleaved, and stabilized trimeric Env proteins based on HIV type 1 Env subtype A.
|
| |
AIDS Res Hum Retroviruses,
22,
569-579.
|
|
|
|
|
|
|
S.Sánchez-Martínez,
M.Lorizate,
H.Katinger,
R.Kunert,
and
J.L.Nieva
(2006).
Membrane association and epitope recognition by HIV-1 neutralizing anti-gp41 2F5 and 4E10 antibodies.
|
| |
AIDS Res Hum Retroviruses,
22,
998.
|
|
|
|
|
|
|
W.Ou,
N.Lu,
S.S.Yu,
and
J.Silver
(2006).
Effect of epitope position on neutralization by anti-human immunodeficiency virus monoclonal antibody 2F5.
|
| |
J Virol,
80,
2539-2547.
|
|
|
|
|
|
|
Y.Eda,
M.Takizawa,
T.Murakami,
H.Maeda,
K.Kimachi,
H.Yonemura,
S.Koyanagi,
K.Shiosaki,
H.Higuchi,
K.Makizumi,
T.Nakashima,
K.Osatomi,
S.Tokiyoshi,
S.Matsushita,
N.Yamamoto,
and
M.Honda
(2006).
Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif.
|
| |
J Virol,
80,
5552-5562.
|
|
|
|
|
|
|
A.S.Dimitrov,
J.M.Louis,
C.A.Bewley,
G.M.Clore,
and
R.Blumenthal
(2005).
Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation.
|
| |
Biochemistry,
44,
12471-12479.
|
|
|
|
|
|
|
B.F.Haynes,
M.A.Moody,
L.Verkoczy,
G.Kelsoe,
and
S.M.Alam
(2005).
Antibody polyspecificity and neutralization of HIV-1: a hypothesis.
|
| |
Hum Antibodies,
14,
59-67.
|
|
|
|
|
|
|
C.Hager-Braun,
and
K.B.Tomer
(2005).
Determination of protein-derived epitopes by mass spectrometry.
|
| |
Expert Rev Proteomics,
2,
745-756.
|
|
|
|
|
|
|
D.R.Burton,
R.L.Stanfield,
and
I.A.Wilson
(2005).
Antibody vs. HIV in a clash of evolutionary titans.
|
| |
Proc Natl Acad Sci U S A,
102,
14943-14948.
|
|
|
|
|
|
|
E.T.Crooks,
P.L.Moore,
D.Richman,
J.Robinson,
J.A.Crooks,
M.Franti,
N.Schülke,
and
J.M.Binley
(2005).
Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization.
|
| |
Hum Antibodies,
14,
101-113.
|
|
|
|
|
|
|
G.J.Nabel
(2005).
Immunology. Close to the edge: neutralizing the HIV-1 envelope.
|
| |
Science,
308,
1878-1879.
|
|
|
|
|
|
|
J.M.Decker,
F.Bibollet-Ruche,
X.Wei,
S.Wang,
D.N.Levy,
W.Wang,
E.Delaporte,
M.Peeters,
C.A.Derdeyn,
S.Allen,
E.Hunter,
M.S.Saag,
J.A.Hoxie,
B.H.Hahn,
P.D.Kwong,
J.E.Robinson,
and
G.M.Shaw
(2005).
Antigenic conservation and immunogenicity of the HIV coreceptor binding site.
|
| |
J Exp Med,
201,
1407-1419.
|
|
|
|
|
|
|
M.B.Zwick
(2005).
The membrane-proximal external region of HIV-1 gp41: a vaccine target worth exploring.
|
| |
AIDS,
19,
1725-1737.
|
|
|
|
|
|
|
R.M.Cardoso,
M.B.Zwick,
R.L.Stanfield,
R.Kunert,
J.M.Binley,
H.Katinger,
D.R.Burton,
and
I.A.Wilson
(2005).
Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41.
|
| |
Immunity,
22,
163-173.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
S.Rao,
S.Hu,
L.McHugh,
K.Lueders,
K.Henry,
Q.Zhao,
R.A.Fekete,
S.Kar,
S.Adhya,
and
D.H.Hamer
(2005).
Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide.
|
| |
Proc Natl Acad Sci U S A,
102,
11993-11998.
|
|
|
|
|
|
|
T.Zhou,
D.H.Hamer,
W.A.Hendrickson,
Q.J.Sattentau,
and
P.D.Kwong
(2005).
Interfacial metal and antibody recognition.
|
| |
Proc Natl Acad Sci U S A,
102,
14575-14580.
|
|
|
PDB codes:
|
|
|
|
|
|
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
 |
|
Links
